CD160 and B-cell chronic lymphocytic leukemia: Given our previous work and that of others, which have highlighted CD160, TIGIT, PD‐1, and CD244 as the most prominent co‐inhibitory receptors expressed among CD8+ T cells in CLL patients [14, 45], we focused on these co‐inhibitory receptors.